Back to Screener

Healthcare

Cognition Therapeutics, Inc.(CGTX)

Live Price

Offline

$1.45

+2.11% today

1Y Change

+346.15%

Window

Jun 26, 2025 β†’ Jun 18, 2026

Market Cap
$90.00M
Revenue Growth
0.0%
EPS Growth
+62.4%
Dividend Yield
0.0%

Coverage: 246 bars Β· Jun 26, 2025 β†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Cognition Therapeutics, Inc. (CGTX) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $1.45 and up 346.2% across the available one-year price window (Jun 26, 2025 β†’ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +62.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +62.4%, free cash flow +13.7% with operating margin 0.0% and ROIC -136.9%. Stock Foundry combines CGTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 6, 2026, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is +62.4%, while operating margin sits near 0.0%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged -9.8% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table
QuarterEPS Ξ”1D5D20D
2026
May 6, 2026
β€”-5.7%-2.4%+10.6%
2026
Mar 26, 2026
+66.7%-32.4%-19.6%+18.5%
2025
Nov 6, 2025
+14.3%+0.0%-7.2%+4.2%

Benchmark Edge

CGTX vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

CGTX

β€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

CGTX Max Drawdown

-81.29%

Trailing 1Y

SPY Max Drawdown

β€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CGTX and SPY.

Calendar-year return history is still loading or unavailable.
Cognition Therapeutics, Inc. logo

Company Overview

Cognition Therapeutics, Inc.

NASDAQ

Purchase, NY, United States
Visit cogrx.com

Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. Its lead candidate, zervimesine (also known as CT1812), is an investigational oral small molecule designed to penetrate the blood-brain and blood-retina barriers, selectively bind to the sigma-2 receptor complex, and restore normal neuronal functions such as autophagy, cholesterol biosynthesis, vesicle trafficking, and protein stabilization. The company is advancing zervimesine through clinical programs in Alzheimer’s disease, including mild-to-moderate and early stages, as well as dementia with Lewy bodies and geographic atrophy secondary to dry age-related macular degeneration. These efforts encompass Phase 2 and planned Phase 3 studies evaluating safety, tolerability, cognition, function, and neuropsychiatric outcomes, alongside expanded access programs. Founded in 2007 and headquartered in Purchase, New York, Cognition Therapeutics Inc. plays a role in addressing unmet needs in neurodegenerative and neuro-ophthalmic diseases by modulating cellular damage response mechanisms.

Leadership
Ms. Lisa Ricciardi
Employees
14
Street Address
2500 Westchester Ave.
Mailing
Purchase, NY, 10577
Region
Purchase, NY, United States
Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
β€”
EV/EBITDA
β€”
Price/Sales
β€”
Price/Book
3.2

Growth

Revenue
0.0%
EPS
+62.4%
Free Cash Flow
+13.7%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-104.3%
ROIC
-136.9%

Balance Sheet

Debt/Equity
0.02
Current Ratio
3.45

Earnings Reports

πŸ“… Last reportedMay 6, 2026
PeriodB/MEPSEPS Ξ”RevenueRev Ξ”
β€”
May 6, 26
β€”
Est -0.06
β€”
β€”
Est 4400.0B
β€”
β€”
Mar 26, 26
βœ“
-0.02
Est -0.06
+66.7%
β€”
Est β€”
β€”
β€”
Nov 6, 25
βœ“
-0.06
Est -0.07
+14.3%
β€”
Est β€”
β€”
β€”
Aug 7, 25
βœ“
-0.11
Est -0.12
+8.3%
β€”
Est β€”
β€”
β€”
May 7, 25
βœ—
-0.14
Est -0.12
-16.7%
β€”
Est β€”
β€”
β€”
Mar 20, 25
βœ—
-0.17
Est -0.16
-6.3%
β€”
Est β€”
β€”
β€”
Nov 13, 24
βœ—
-0.25
Est -0.24
-4.2%
β€”
Est β€”
β€”
β€”
Aug 8, 24
βœ“
-0.18
Est -0.22
+18.2%
β€”
Est β€”
β€”
β€”
May 7, 24
βœ—
-0.27
Est -0.23
-17.4%
β€”
Est β€”
β€”
β€”
Mar 26, 24
βœ“
-0.27
Est -0.38
+28.9%
372.0B
Est β€”
β€”
β€”
Nov 2, 23
βœ“
-0.22
Est -0.31
+29.0%
β€”
Est β€”
β€”
β€”
Aug 8, 23
βœ“
-0.16
Est -0.25
+36.0%
β€”
Est β€”
β€”
β€”
May 4, 23
βœ—
-0.21
Est -0.17
-23.5%
β€”
Est β€”
β€”
β€”
Mar 23, 23
βœ“
-0.20
Est -0.49
+59.2%
β€”
Est β€”
β€”
β€”
Nov 14, 22
βœ“
-0.29
Est -0.55
+47.3%
β€”
Est β€”
β€”
β€”
Aug 9, 22
βœ“
-0.25
Est -0.31
+19.4%
β€”
Est β€”
β€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks